IDH1/2 mutations are observed in 15 to 20% of ICC cases [31, 32] and result in the production of the 2-hydroxyglutarate (2-HG), which inhibits the , 2-HG contributes to maintaining (TET) proteins [33]. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.